A phase 1/2 clinical trial of IC-100
Latest Information Update: 09 May 2021
At a glance
- Drugs IC 100 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man; Therapeutic Use
- 05 May 2021 According to an IVERIC bio media release, the Company now believes that IC-100 will likely be delayed from entering into a Phase 1/2 clinical trial this year.
- 09 Mar 2021 New trial record
- 03 Mar 2021 According to an IVERIC bio media release, company is preparing an IND for IC-100 and plans to meet with regulatory authorities to discuss its selected doses for a first-in-human clinical trial prior to the submission. The Company plans to file an IND for IC-100 with the FDA and begin enrolling patients in this trial in the second half of 2021.